Physician profile
Nirali M Dubal
NPI 1386699403
$591.52
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $161 · 2021: $17.60 · 2022: $75.12 · 2023: $80.99 · 2024: $65.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $146.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $91.52 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $70.43 | 2019-2020 | |
| Tris Pharma INC | $69.13 | 2019-2022 | |
| Sanofi Pasteur INC. | $58.30 | 2019-2023 | |
| Adlon Therapeutics L.P. | $57.57 | 2019-2020 | |
| Cranial Technologies, INC | $54.13 | 2019-2023 | Doc Band |
| Corium, LLC | $43.24 | 2024 | Azstarys |
| Glaxosmithkline, LLC. | $31.70 | 2020-2021 | |
| Pfizer INC. | $31.37 | 2019-2020 | |
| Kyowa Kirin, INC. | $22.06 | 2024 | Crysvita |
| Smith+Nephew, INC. | $17.49 | 2020 | |
| Vertical Pharmaceuticals, LLC | $17.21 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.44 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.93 | 2023 | Flumist Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirali Dubal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.